rate. Stock price in terms of fair market value is in the $1.00 - $1.30 range...
Not a short just making an objective observation.
"from twitter.....median OS has not yet been reached in bavituximab treatment arms, says Dr David Gerber, lead study investigator @ media briefing"
Importantly, though median OS has not yet been reached in either bavituximab-containing cohort, there is a clear and persistent separation of the survival curves warranting further development of bavituximab.
not going to help cash position much...
Applied Materials Buying Advent Solar, Cheap: While the amount for the deal is not being disclosed, it “was done very cheaply,” Lux Research analyst Ted Sullivan told us. “Investors did not get their money back — pennies on the dollar is a very safe assumption.”
link => http://earth2tech.com/2009/11/07/earth2tech-week-in-review-65/